Leukemias and lymphomas: Treatment and prophylaxis of the central nervous system

被引：8

作者：

Franklin J.L. ^{[1
]}

Finlay J. ^{[1
]}

机构：

[1] Children's Hospital Los Angeles, Los Angeles, CA 90027

来源：

Current Treatment Options in Neurology | 2006年 / 8卷 / 4期

关键词：

Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Main Drug Interaction; Primary Central Nervous System Lymphoma; Central Nervous System Disease;

D O I：

10.1007/s11940-006-0023-9

中图分类号：

学科分类号：

摘要：

Central nervous system (CNS)-directed therapy is required for many acute leukemia patients and for nearly all aggressive or high-grade non-Hodgkin's lymphoma patients as part of an overall chemotherapy plan for disease eradication. The CNS therapy decisions differ for overt disease treatment versus prophylactic treatment and take into consideration the type of leukemia or lymphoma, the age of the patient, and other prognostic factors. A variety of CNS-directed therapies are used for prevention or treatment of CNS disease in acute leukemias or aggressive lymphomas: intrathecal medications (cytosine arabinoside, methotrexate, or both in combination with hydrocortisone) with or without cranial or craniospinal irradiation, intrathecal medication only with intensive systemic chemotherapy, or high-dose chemotherapy specifically chosen for CNS penetrance. Any type of CNS-directed therapy, whether intrathecal chemotherapy, high-dose systemic chemotherapy, or irradiation, may cause acute or delayed (late) toxicity. Ongoing clinical trial research aims to reduce the risk of toxicity from CNS-directed therapy while preserving or improving treatment efficacy. Copyright © 2006 by Current Science Inc.

引用

页码：335 / 345

页数：10

共 61 条

[1]

Bleyer W.A., Poplack D.A., Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries, Semin Oncol, 12, pp. 131-148, (1985)

[2]

Gokbuger N., Hoeltzer D., Meningeosis leukaemica in adult acute lymphoblastic leukemia, J Neurol Oncol, 38, pp. 167-180, (1998)

[3]

Keldsen N., Michalski W., Bentzen S.M., Et al., Risk factors for central nervous system involvement in non-Hodgkin's lymphoma, Acta Oncol, 35, pp. 703-708, (1996)

[4]

Horak I.D., Kremer A.B., Magrath I.T., Management of histologically aggressive lymphomas with a high risk of CNS disease, Baillieres Clin Haematol, 9, pp. 707-727, (1996)

[5]

Van Dongen-Melman J.E., De Groot A., Van Dongen J.J., Et al., Cranial irradiation is the major cause of learning problems in children treated for leukemia and lymphoma: A comparative study, Leukemia, 11, pp. 1197-2000, (1997)

[6]

Haddy T.B., Adde M.A., McCalla J., Et al., Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas, J Clin Oncol, 16, pp. 2070-2079, (1998)

[7]

Claviez A., Neubauer B., Link J., Scheppenheim R., Intracerebral hemorrhage as a late complication after CNS treatment of childhood lymphoma, Klin Padiatr, 210, pp. 406-408, (1998)

[8]

Loning L., Zimmerman M., Reiter A., Et al., Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: Significantly lower risk without cranial radiotherapy, Blood, 95, pp. 2770-2775, (2000)

[9]

Margolin J.F., Poplack D.G., Acute lymphoblastic leukemia, Principles and Practice of Pediatric Oncology, (2005)

[10]

Sham R.L., Phatak P.D., Kouides P.A., Et al., Hematologic neoplasia and the central nervous system, Am J Hematol, 62, pp. 234-238, (1999)

← 1 2 3 4 5 6 7 →